Kamada (KMDA)

[midastouch017]

Analysts Anticipate Kamada Ltd. (NASDAQ:KMDA) Will Post Quarterly Sales of $33.17 Million

https://www.marketbeat.com/instant-alerts/nasdaq-kmda-consensus-analyst-rating-2021-01/

FRIDAY, JANUARY 15, 2021 | MARKETBEAT
Kamada logoAnalysts expect Kamada Ltd. (NASDAQ:KMDA) to announce $33.17 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Kamada's earnings. The lowest sales estimate is $32.40 million and the highest is $33.93 million. Kamada posted sales of $32.07 million in the same quarter last year, which would indicate a positive year over year growth rate of 3.4%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, February 10th.

On average, analysts expect that Kamada will report full-year sales of $134.75 million for the current financial year, with estimates ranging from $134.10 million to $135.64 million. For the next fiscal year, analysts anticipate that the business will report sales of $103.23 million, with estimates ranging from $98.30 million to $106.70 million. Zacks' sales averages are an average based on a survey of research firms that cover Kamada.

Kamada (NASDAQ:KMDA) last released its earnings results on Wednesday, November 11th. The biotechnology company reported $0.15 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.08 by $0.07. The firm had revenue of $35.33 million during the quarter, compared to analyst estimates of $33.49 million. Kamada had a return on equity of 12.89% and a net margin of 15.60%.

Kamada stock opened at $7.23 on Friday. The firm has a market capitalization of $321.88 million, a P/E ratio of 15.06 and a beta of 1.10. The stock has a fifty day moving average price of $6.60 and a 200 day moving average price of $8.00. Kamada has a 52 week low of $4.40 and a 52 week high of $13.33.

A number of large investors have recently made changes to their positions in the business. Ritholtz Wealth Management increased its stake in Kamada by 17.2% during the third quarter. Ritholtz Wealth Management now owns 34,276 shares of the biotechnology company's stock worth $287,000 after acquiring an additional 5,039 shares during the last quarter. Bank of America Corp DE acquired a new stake in Kamada during the second quarter worth about $56,000. O Shaughnessy Asset Management LLC increased its stake in Kamada by 10.0% during the third quarter. O Shaughnessy Asset Management LLC now owns 85,892 shares of the biotechnology company's stock worth $718,000 after acquiring an additional 7,825 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in Kamada during the second quarter worth about $84,000. Finally, Jane Street Group LLC increased its stake in Kamada by 61.9% during the third quarter. Jane Street Group LLC now owns 32,090 shares of the biotechnology company's stock worth $268,000 after acquiring an additional 12,268 shares during the last quarter. Institutional investors own 14.25% of the company's stock.